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Background: Genetic counselling and testing for Lynch syndrome have recently been introduced in several South
American countries, though yet not available in the public health care system.
Methods: We compiled data from publications and hereditary cancer registries to characterize the Lynch syndrome
mutation spectrum in South America. In total, data from 267 families that fulfilled the Amsterdam criteria and/or
the Bethesda guidelines from Argentina, Brazil, Chile, Colombia and Uruguay were included.
Results: Disease-predisposing mutations were identified in 37% of the families and affected MLH1 in 60% and
MSH2 in 40%. Half of the mutations have not previously been reported and potential founder effects were
identified in Brazil and in Colombia.
Conclusion: The South American Lynch syndrome mutation spectrum includes multiple new mutations, identifies
potential founder effects and is useful for future development of genetic testing in this continent.
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Since the initial reports on disease-predisposing mutations
in the mismatch-repair (MMR) genes MLH1 [MIM:120436],
MSH2 [MIM:609309] and MSH6 [MIM:600678] in the early
1990’ies, a large number of studies have contributed to the
establishment of the molecular map of Lynch syndrome
with over 3,072 unique genetic MMR gene variants identi-
fied. These data are predominantly based on studies from
North America, Europe and Asia. The mutations affect
MLH1 in 42%, MSH2 in 33%, MSH6 in 18% and PMS2 in
8% [1]. Nonsense mutations, frameshift mutations and
missense mutations predominate, whereas large genomic
rearrangements and splice-site variants constitute <10% of
the alterations [1].
The South American population is ethnically mixed from
American Indian and European ancestors. In Uruguay
and Argentina, European ancestry predominates. In Brazil,* Correspondence: mev_dv@yahoo.com
1The Danish HNPCC Register, Clinical Research Centre, Hvidovre Hospital,
Copenhagen University, Hvidovre, Denmark
2Department of Oncology, Institute of Clinical Sciences, Lund University,
Lund, Sweden
Full list of author information is available at the end of the article
© 2013 Dominguez-Valentin et al.; licensee Bio
the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumsignificant African and American Indians roots apply. In
Chile, Colombia, Peru and Bolivia, Spanish colonist and
American Indian ancestry influence the populations [2,3].
Mutation screening in South American families suspected
of Lynch syndrome has identified disease-predisposing
germline mutations in MLH1 and MSH2 in 16-45% of
families that fulfill the Amsterdam criteria and/or the
Bethesda guidelines [2-7]. Hereditary colorectal cancer
registries have been established in Argentina, Brazil,
Uruguay and Chile with the aim to collect and share data
on the MMR gene mutation spectrum, identify potential
founder mutations, interpret the role of unclassified gen-
etic variants and to study cancer risks in the South Ameri-
can Lynch syndrome population. We used published data
and unpublished register data to describe the mutation
spectrum in South American Lynch syndrome families.Methods
Ethics statement
All patients provided an informed consent for inclu-
sion into the South American registers during geneticMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Flowchart of South American patients/families included in the study.
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Helsinki Declaration.
Patient selection
Families that fulfilled the Amsterdam criteria [8,9] and/
or the Bethesda guidelines [10] were selected from the
hereditary cancer registries at the Hospital Italiano (Buenos
Aires, Argentina), the Hospital de las Fuerzas Armadas
(Montevideo, Uruguay), the Clinica Los Condes (Santiago,
Chile), the Barretos Cancer Hospital (Barretos, Brazil) and
from two databases in Colombia and in Southeastern Brazil
(Figure 1, Table 1) [2,3,5,11]. Patients were informed about
their inclusion into the registries, which generally contained
data on family history, age at onset and results of genetic
testing.
Disease-predisposing mutations
Methods to assess MMR status, e.g. microsatellite instabil-
ity analysis and MMR protein staining, varied between the
countries and were excluded from the present study sinceTable 1 Summary of register data from MMR South American




Hospital Italiano (Buenos Aires, Argentina) 28 14
Hospital de las Fuerzas Armadas
(Montevideo, Uruguay)
25 7
Clinica Las Condesa (Santiago, Chile) 50 20
Barretos Cancer Hospitala (Barretos, Brazil) 23 15
Colombiac 13 8
Southeastern Brazilb 128 35
Total 267 99
aMLPA analysis included, bValentin et al. 2011 [3] and Rossi et al. 2002 [5], cGiraldo
available, MMR mismatch-repair genes, SD standard deviation, CRC colorectal cancethese data were incomplete. Molecular diagnosis was
generally based on direct sequencing of MLH1 and MSH2.
Chilean and Brazilian families were also analyzed for
large genomic rearrangements using the multiplex
ligation-dependent probe amplification (MLPA) method
(performed using the SALSA kit P003, MRC-Holland,
Amsterdam, Netherlands).
Mutation nomenclature
Mutation nomenclature was in accordance with the
Human Genome Variation Society (HGVS) guidelines
[12]. Mutations in the MLH1 or MSH2 genes were consid-
ered deleterious if they: a) were classified as pathogenic in
LOVD database; b) introduced a premature stop codon in
the protein sequence (nonsense or frameshift mutation);
c) occurred at donor or acceptor splice sites; or d) repre-
sented whole-exon deletions or duplications. All identified
mutations were correlated to the MMR Gene Unclassified
Variants Database (www.mmruv.info), the Mismatch







Mean age at endometrial
cancer diagnosis
50.0 44.3 (SD 6.2) 46.3 (SD 5.5)
28.0 35.1 (SD 7.6) 41.5 (SD 8.3)
40.0 35.7 (SD 10.7) 41.1 (SD 8.8)
65.2 39.4 (SD 13.8) 49.8 (SD 5.3)
61.5 NA NA
27.3 42.3 (SD 11.4) 48.8 (SD 2.4)
37.1
et al. 2005 [2] and Alonso-Espinaco et al. 2011 [11], NA Information not
r.
Table 2 Spectrum of alterations in South American Lynch syndrome families
Gene Nucleotide Consequence Exon Reported as Country Number of
families
References
MLH1 c.1-?_116 + ?del p.M1_C39 > FfsX13 1 Causal Chile 2 InSIGHT
c.199G > A p.G67R 2 Causal Argentina 1 InSIGHT
c.211G > T p.E71X 3 Causal Brazil 1 InSIGHT
c.289 T > G p.Y97D 3 VUS Uruguay 1 InSIGHT
C.336 T > A p.H112Q 4 VUS Argentina 1 InSIGHT
c.350C > T p.T117M 4 Causal Uruguay 2 InSIGHT
c.421C > G p.P141A 5 VUS Colombia 1 Giraldo et al. 2005 [2]
c.503dupA p.N168KfsX4 6 Causal Chile 1 InSIGHT
c.503delAa p.N168IfsX34 6 Causal Brazil 1 Not previously
described
c.545 + 3A > G 6 Causal Brazil 2 InSIGHT
c.588 + 2 T > Aa 7 Causal Brazil 1 Valentin et al.
2011 [3]
c.588 + 5G > C 7 Causal Brazil 1 InSIGHT
c.665delA p.N222MfsX7 8 Causal Uruguay 2 InSIGHT
c.676C > T p.R226X 8 Causal Argentina 1 InSIGHT
c.677G > A p.R226Q 8 Causal Argentina, Brazil 3 InSIGHT
c.677 + 5G > A 8 Likely causal Chile 1 French MMR network
c.779 T > G p.L260R 9 Causal Brazil 1 InSIGHT
c.790 + 1G > A 9 Causal Chile, Colombia 3 InSIGHT
c.791-
6_793delgtttagATCa
10 Causal Brazil 1 Valentin et al.
2011 [3]
c.794G > C p.R265P 10 VUS Chile 1 InSIGHT
c.901C > T p.Q301X 11 Causal Chile 1 InSIGHT
c.1013A > Ga p.N338S 11 VUS Brazil 1 InSIGHT
c.1038 + 1G > Ta p.Y347FfsX13 11 Causal Chile 1 Wielandt et al. 2012
c.1039-8T_1558?
896Tdupa
p.520Vfs564X 12 to 13 Causal Colombia 2 Alonso-Espinaco et al.
2011 [11]
c.1276C > T p.Q426X 12 Causal Brazil 3 InSIGHT
c.1459C > T p.R487X 13 Causal Brazil 1 InSIGHT
c.1499_1501delTCAa p.I500del 13 Causal Brazil 1 Rossi et al. 2002 [5]
c.1558 + 1G > T 13 Causal Brazil 1 InSIGHT
c.1558 + 14G > A 13 VUS Colombia 2 InSIGHT
c.1559-2A > C 13 Causal Chile 1 InSIGHT
c.1559-?_1731 + ?del p.V520_S577 > GfsX7b 14 -15 Causal Chile 1 Wielandt et al. 2012
c.1639_1643dup TTATAa p.L549YfsX44 14 Causal Brazil 1 Valentin et al. 2011
[3]
c.1690_1693delCTCA p.L564FfsX26 15 Causal Brazil 1 InSIGHT
c.1724G > A p.R575K 15 VUS Argentina 1 InSIGHT
c.1731 + 3A > Ta Skipping exon 15 15 Causal Chile 1 Alvarez et al. 2010 [6]
c.1846delAAG p.K616del 16 Causal Argentina 1 InSIGHT
c.1852_1853delinsGC p.K618A 16 Causal Argentina 1 InSIGHT
c.1852_1854 delAAG p.K618del 16 Causal Argentina 1 InSIGHT
c.1853A > C p.K618T 16 VUS Brazil 1 InSIGHT
c.1853delAinsTTCTTa p.K618IfsX4 16 Causal Brazil 2 Valentin et al.
2011 [3]
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Table 2 Spectrum of alterations in South American Lynch syndrome families (Continued)
c.1856delGa 16 Causal Colombia 2 Giraldo et al. 2005 [2]
c.1890dupa p.D631fsX1 16 Causal Argentina 1 Valentin et al.
2011 [3]
c.1897-?_1989 + ?dela 17-19 Causal Brazil 1 Not previously
described
c.1918C > T p.P640T 17 VUS Colombia 1 InSIGHT
c.1975C > T p.R659X 17 Causal Brazil 1 InSIGHT
c.1998G > A p.W666X 18 Causal Brazil 1 Rossi et al. 2012 [5]
c.2027 T > C p.L676P 18 Causal Brazil 1 InSIGHT
c.2041G > A p.A681T 18 Likely causal Chile, Brazil,
Colombia
4 French MMR network
c.2092_2093delTC p.S698RfsX5 18 Causal Chile 1 Alvarez et al. 2010 [6]
c.2224C > Ta p.Q742X 19 Causal Brazil 1 Valentin et al.
2011 [3]
c.2252_2253dupAA p.V752KfsX26 19 VUS Brazil 1 InSIGHT
c.2104-?_2271 + ?delb p.S702_X757del 19 Causal Chile 2 Wielandt et al. 2012
MSH2 c.71delAa p.Q24fs 1 Causal Brazil 1 Not previously
described
c.166G > Ta p.E56X 1 Causal Argentina 1 InSIGHT
c.174dupCa 1 Causal Brazil 1 Not previously
described
c.175dupCa p.K59QfsX23 1 Causal Brazil 1 Valentin et al.
2011 [3]
c.181C > Ta p.Q61X 1 Causal Uruguay 1 Sarroca et al. 2003
c.187delG p.V63fsX1 1 Causal Brazil 1 InSIGHT
c.289C > T p.Q97X 2 Causal Argentina 1 InSIGHT
c.212-?_366 + ?del p.A72_K122 > FfsX9 2 Causal Chile 1 InSIGHT
c.388_389delCA p.Q130VfsX2 3 Causal Brazil, Argentina 2 InSIGHT
c.530_531delAAa p.E177fsX3 3 Causal Uruguay 1 Sarroca et al. 2003
c.596delTGa 3 Causal Colombia 1 Giraldo et al. 2005 [2]
c.862C > T p.Q287X 5 Causal Brazil 1 InSIGHT
c.897 T > G p.Y299X 5 Causal Chile 1 Wielandt et al. 2012
c.942 + 3 A > T 5 Causal Brazil 1 InSIGHT
c.1077-?_1276 + ?del p.L360KfsX16 7 Causal Argentina 1 InSIGHT
c.1147C > T p.R382X 7 Causal Brazil 1 InSIGHT
c.1215C > A p.Y405X 7 Causal Chile 1 InSIGHT
c.1216C > T p.R406X 7 Causal Uruguay 1 InSIGHT
c.1249delG p.V417LfsX21 7 Causal Brazil 1 InSIGHT
c.1255C > T p.Q419X 7 Causal Brazil 1 InSIGHT
c.1444A > Ta p.R482X 9 Causal Brazil 1 Valentin et al.
2011 [3]
c.1447G > T p.E483X 9 Causal Brazil 2 InSIGHT
c.1667delTa p.L556X 11 Causal Brazil 1 Valentin et al.
2011 [3]
c.1667_1668insAa p.T557DfsX5 11 Causal Brazil 1 Rossi et al. 2002 [5]
c.1910delCa p.R638GfsX47 12 Causal Argentina 1 Vaccaro et al. 2007
c.1967_1970dupACTTa p.F657LfsX3 12 Causal Brazil 1 Valentin et al.
2011 [3]
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Table 2 Spectrum of alterations in South American Lynch syndrome families (Continued)
c.2038C > T p.R680X 13 Causal Chile 1 InSIGHT
c.2046_2047delTGa p.V684Dfs*14 13 Causal Argentina 1 InSIGHT
c.2131C > T p.R711X 13 Causal Brazil 1 InSIGHT
c.2152C > T p.Q718X 13 Causal Brazil 6 InSIGHT
c.2185_2192del7insCCCTa p.
M729_E731delinsP729_X730
13 Causal Chile 1 Alvarez et al. 2010 [6]
c.2187G > Ta p.M729I 13 VUS Brazil 1 Valentin et al.
2011 [3]
c.2525_2526delAGa p.E842VfsX3 15 Causal Brazil 2 Valentin et al.
2011 [3]
c.2785C > Ta p.R929X 16 Causal Brazil 1 Valentin et al.
2011 [3]
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Figure 2 Spectrum of pathogenic mutations in MLH1 and MSH2
genes a) Types of pathogenic germline mutations; b) Distribution
along all exons of the MMR genes.
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umd.be/MMR.html) and the International Society for
Gastrointestinal Hereditary Tumors (InSIGHT) (http://
www.insight-group.org).
Variants of uncertain significance
To establish the pathogenicity of variants of uncertain
significance, web-based programs, i.e. Polyphen, MAPP-
MMR, SIFT, P-mut and PON-MMR were applied to
predict the effect of an amino acid substitution based
on protein structural change and/or evolutionary con-
servation [13-17].
Statistical analysis
The statistical analyses were performed using the statis-
tical software package IBM SPSS Statistics 20 (SPSS,
Chicago, IL, USA).
Results
In total, 110 families harbored MMR gene variants, of
which 99 were classified as Lynch syndrome predispos-
ing and 11 were regarded as variants of uncertain signifi-
cance. Mutations in MLH1 and MSH2 were identified in
37% (range 27-65% in the different countries/registries)
of the families that fulfilled the Amsterdam criteria and/
or Bethesda guidelines (Table 1). When the Amsterdam
criteria were considered, the mutation detection rate was
55% (81/147), whereas 15% families that fulfilled the
Bethesda guidelines had disease-predisposing mutations.
The mean age at diagnosis was 35–44 years for colorectal
cancer and 41–49 years for endometrial cancer in the dif-
ferent registries (Table 1). Pedigree information was avail-
able from 54 families and showed that among the Lynch
syndrome-associated tumors, 65% were colorectal cancers
(of which 43% were located in the right side of the colon),
22% endometrial cancers and 13% constituted other Lynch
syndrome-associated cancer types.Of the 99 disease-predisposing MMR gene mutations,
60% affected MLH1 and 40% affected MSH2 (Table 2).
Frameshift and nonsense mutations were the most com-
mon alterations (36% and 31%, respectively), followed by
splice site mutations (13%), missense mutations (12%)
and large deletions (8%) (Figure 2a). Though the muta-
tions were spread over the genes, hot-spot regions in-
cluded exons 16 and 18 in MLH1 (13% of the mutations
Dominguez-Valentin et al. Hereditary Cancer in Clinical Practice 2013, 11:18 Page 6 of 9
http://www.hccpjournal.com/content/11/1/18each) and exon 13 in MSH2 (24% of the mutations each)
(Figure 2b).
In total, 10 mutations identified in at least two South
American families were classified as recurrent. Among
these, the MSH2 c.2152C > T identified in Brazil repre-
sents an internationally hot-spot. Three founder mutations
were identified in five South American families. The
MLH1 c.545 + 3A >G and the MSH2 c.942 + 3A > T have
been identified as founder mutations in Italy and in New-
foundland and were also identified in Brazilian families
[3]. The MLH1 c.1039-8T_1558 + 896Tdup has been sug-
gested to represent a founder mutation in Colombia
[2,11]. Mutations that were unique and herein first re-
ported in more than one family included the MLH1
c.1853delAinsTTCTT in Brazil, the MLH1 c.1856delG in
Colombia and the MSH2 c.25252_2526delAG in Brazil
(Table 2) (Figure 3).
In total, 11 variants of unclassified significance were iden-
tified in individuals from Argentina, Uruguay, Chile, Brazil








Figure 3 Map of South America showing the countries where
Lynch syndrome families with the founder, recurrent, unique
mutations and variants of unclassified significance (VUS) have
been identified. The figure depicts the countries participating in
the study (gray). The pie chart represents in percentage the
recurrent mutations, unique mutations, founder mutations and VUS
identified in the South American families. Brazil is characterized by
16% of the founder mutations, 39% of the recurrent mutations, 14%
of the unique mutations and 31% of the VUS, while Colombia by
20% of the founder mutations, 20% of the unique mutations and
60% of the VUS. Chile, Argentina and Uruguay are characterized by
80%, 50% and 67% of the recurrent mutations and 20%, 50% and
33% of the VUS, respectively.that the MLH1 c.289 T > G, the MLH1c.794G > C and
the MLH1c.1918C > T were likely disease-predisposing
(Table 3).Discussion
In South America, disease-predisposing mutations
linked to Lynch syndrome have been identified in 99
families, which corresponds to 37% of the families that
fulfilled the Amsterdam criteria and/or Bethesda guide-
lines and underwent genetic testing. The mutation rate
is high compared to prevalence rates of 28% for MLH1
and 18% for MSH2 in the Asian population, 31% and
20% in a multi-ethnic American population and 26%
and 19% in European/Australian populations [18]. The
mutation spectrum is predominated by MLH1 (60%)
and MSH2 (40%) mutations [3,19-22], but the seemingly
larger contribution than the 42% and 33% reported in the
InSIGHT database could reflect failure to test for MSH6
and PMS2 mutations in most South American studies [1].
Referral bias in populations that have more recently been
screened for mutations represents a potential limitation,
but the strong contribution from MLH1 and MSH2 could
also reflect population structure [2,4,5,7]. Frameshift mu-
tations and nonsense mutations were the most common
types of mutations, which are in agreement with findings
from other populations [1,23-26], with hotspots in exons
16 and 18 of MLH1 and in exon 13 of MSH2 (Figure 2b).
Exon 16 and 18 in MLH1 has been identified as a
genetic hot spot also in other populations with 26% of
the MLH1 mutations reported herein [3,18]. The fre-
quent mutations in MSH2 exon 13 may be linked to
the c.2152C>, which was first identified in Portuguese
Lynch syndrome families. This alteration accounted
for 35% (6/17) of the MSH2 mutations in the Brazilian
population, which is in line with the Portuguese migra-
tion to Brazil [3,27].
Founder mutations have been identified in several
populations where they significantly contribute to dis-
ease predisposition and thereby allow for directed gen-
etic testing [28]. Two of the mutations identified in
South American Lynch syndrome families have been
suggested to constitute potential founder mutations in
other populations, e.g. the Italian MLH1 c.545 + 3A > G
and the Newfoundland MSH2 c.942 + 3A > T [3]. The
Spanish founder mutations MLH1 c.306 + 5G > A and
c.1865 T > A and MSH2 c.2635-3 T > C; c2635-5C > T;
c.2063 T > G were, however, not observed in South
American Lynch syndrome families [27-30]. In Colombia,
the MSH2 c.1039-8T_1558 + 896Tdup was suggested to
represent a founder mutation [2,11]. The Colombian
population has a mixed ancestry with a strong influence
from Spanish colonists and thereby genetically differs from
previously studied populations [2,6].
Table 3 Variants of unclassified significance and in silico prediction in South American Lynch syndrome families
Country Gene Nucleotide Consequence Exon Polyphen SIFT MAP_MMR P-mut PON-MMR
Score Classification Score Classification Score Classification Score Classification Score Classification
Uruguay MLH1 c.289 T > G p.Y97D 3 0.999 Probably damaging 0 Damaging 10.51 Damaging 0.7266 Pathological 0.83 Pathogenic
Argentina MLH1 c.336 T > A p.H112Q 4 1 Probably damaging 0.03 Damaging 2.430 Neutral NA NA 0.61 VUS
Colombia MLH1 c.421C > G p.P141A 5 0.329 Benign 0.05 Damaging 3.15 Borderline deleterious 0.4928 Neutral 0.48 VUS
Chile MLH1 c.794G > C p.R265P 10 1 Probably damaging 0 Damaging 38.09 Damaging 0.7623 Pathological 0.83 Pathogenic
Brazil MLH1 c.1013A > G p.N338S 11 0.506 Possibly Damaging 0.05 Damaging 2.78 Neutral 0.2551 Neutral 0.38 VUS
Colombia MLH1 c.1558 + 14G > A 13 NA NA NA NA NA NA NA NA NA NA
Argentina MLH1 c.1724G > A p.R575K 15 0.001 Benign 0.40 Tolerated 1.490 Neutral NA NA 0.15 Neutral
Brazil MLH1 c.1853A > C p.K618T 16 0.997 Probably damaging 0.02 Damaging 5.11 Damaging 0.7802 Pathological 0.67 VUS
Colombia MLH1 c.1918C > T p.P640T 17 1 Probably damaging 0 Damaging 17.77 Damaging 0.6534 Pathological 0.83 Pathogenic
Brazil MLH1 c.2252_2253dupAA p.V752Kfs*26 19 NA NA NA NA NA NA NA NA NA NA
Brazil MSH2 c.2187G > T p.M729I 13 2.293 Probably damaging 0 Damaging 21.99 Damaging 0.1988 Neutral 0.71 VUS
MLH1 (MIM#120436), MSH2 (MIM#609309), NA: not applicable, VUS: variants of unclassified significance, If SIFT score <0.05 then the aminoacid (AA) substitution is predicted to affect protein function, if PolyPhen score
>0.5 then the AA substitution is predicted to affect protein function, if MAPP-MMR score >4.55 then the AA substitution is predicted to affect protein function, If P-mut score > 0.5, the AA substitution is classified as
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In conclusion, disease-predisposing mutations in MLH1
and MSH2 have been identified in a relatively large pro-
portion of the South American families suspected of
Lynch syndrome that have been tested. Genetic hot-spot
regions, internationally recognized founder mutations
and potential South American founder mutation have
been recognized, which is of relevance for genetic coun-
seling and testing that are increasingly available in South
America.
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